Dowpharma Introduces Next Generation Microbial Expression System for Production of Biotherapeutics

Dowpharma, a business unit of The Dow Chemical Company, is pleased to introduce the next generation of microbial expression technologies for the production of recombinant proteins. This new technology platform is built around specially designed strains of Pseudomonas fluorescens that increase cellular expression while maintaining critical solubility and activity characteristics of recombinant proteins. Dowpharma has demonstrated that this technology delivers significant benefits not typically realized using other microbial host cell systems.

"We have found that this system consistently outperformed existing microbial expression platforms and also delivers advantages in recovery and purification," says Nick Hyde, business director, Dowpharma. "This improved performance will positively impact our biopharmaceutical customers' bottom lines.

"Furthermore, because we have fully sequenced, annotated and researched the genome, we can quickly and easily modify the strains to increase the expression of a particular client's biotherapeutic. This will help speed our customers to the clinic with a reliable, robust manufacturing program." Fermentation using Dow's Pseudomonas fluorescens expression technology is carried out at high cell density using only soluble, defined mineral salts media containing no animal-derived components or antibiotics. Fermentation is also readily scalable.

In the coming year, Dowpharma will be presenting data at conferences in both the U.S. and Europe, describing the performance of P. fluorescens in the production of therapeutic proteins.

For further information on how this next generation technology can benefit your biopharmaceutical program, please contact Patrick Lucy, Director of Business Development, Dowpharma, Biopharmaceutical Contract Manufacturing Services, at pklucy@dow.com, or by visiting our website at www.dowpharma.com.